发布求助
文献互助 智能选刊 最新文献

International Journal of Hematologic Oncology最新文献

筛选
英文 中文
Management of multiple myeloma: the impact of ixazomib's approval in Canada. 多发性骨髓瘤的治疗:ixazomib在加拿大获批的影响
International Journal of Hematologic Oncology Pub Date : 2016-11-01 Epub Date: 2017-01-13 DOI: 10.2217/ijh-2016-0014
Donna E Reece
{"title":"Management of multiple myeloma: the impact of ixazomib's approval in Canada.","authors":"Donna E Reece","doi":"10.2217/ijh-2016-0014","DOIUrl":"https://doi.org/10.2217/ijh-2016-0014","url":null,"abstract":"<p><p><b>Donna E Reece speaks to Laura Dormer, Commissioning Editor:</b> Dr Donna E Reece is a Professor of Medicine and Director of the Program for Multiple Myeloma and Related Diseases in the Department of Medical Oncology and Hematology at Princess Margaret Hospital/University of Toronto. She earned a Bachelor of Arts degree at the University of Texas, Austin, and graduated as valedictorian with a medical degree from Baylor College of Medicine, Houston, Texas. She completed an internship in Internal Medicine at the University of Colorado Affiliated Hospitals, a residency and Chief Residency in Internal Medicine at Jewish Hospital, St Louis, and a Fellowship in Hematology/Oncology at Barnes Hospital, Washington University, St Louis, Missouri. She was a fellow and later a leukemia/stem cell transplant staff physician at Vancouver General Hospital/University of British Columbia for over 10 years. She then served as Director of the Outpatient Leukemia/Stem Cell Transplant Program, and later interim director, of the Blood and Marrow Transplant Program of the Markey Cancer Center at the University of Kentucky, Lexington, Kentucky until her appointment to Princess Margaret Hospital in Toronto in 2001. Dr Reece received the David and Molly Bloom Chair in Myeloma Research in 2009. She is currently the co-chair of the Multiple Myeloma Clinical Trials Group of the National Cancer Institute of Canada, member of the Scientific Advisory Board of the International Myeloma Foundation, and member of the Project Review Committee of the MMRC (Multiple Myeloma Research Consortium). She is also the Chief Medical Officer of the Myeloma Canada Research Network and serves on the board of directors of Myeloma Canada. Her career focus has been in the areas of hematopoietic stem cell transplantation, lymphoid malignancies and plasma cell dyscrasias. She has published numerous articles in these areas.</p>","PeriodicalId":14166,"journal":{"name":"International Journal of Hematologic Oncology","volume":"5 3","pages":"97-99"},"PeriodicalIF":0.0,"publicationDate":"2016-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/ijh-2016-0014","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36568858","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Current treatment options in elderly patients with chronic lymphocytic leukemia. 老年慢性淋巴细胞白血病患者目前的治疗选择。
International Journal of Hematologic Oncology Pub Date : 2016-09-01 Epub Date: 2016-09-23 DOI: 10.2217/ijh-2016-0006
Stefano Molica
{"title":"Current treatment options in elderly patients with chronic lymphocytic leukemia.","authors":"Stefano Molica","doi":"10.2217/ijh-2016-0006","DOIUrl":"https://doi.org/10.2217/ijh-2016-0006","url":null,"abstract":"","PeriodicalId":14166,"journal":{"name":"International Journal of Hematologic Oncology","volume":"5 2","pages":"55-57"},"PeriodicalIF":0.0,"publicationDate":"2016-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/ijh-2016-0006","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36612058","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Five-year direct costs of acute lymphoblastic leukemia pediatric patients undergoing allogeneic stem cell transplant. 急性淋巴细胞白血病儿童患者接受同种异体干细胞移植的5年直接成本。
International Journal of Hematologic Oncology Pub Date : 2016-09-01 Epub Date: 2016-04-27 DOI: 10.2217/ijh-2016-0001
Richard T Maziarz, Annie Guérin, Geneviève Gauthier, Julie Heroux, Maryia Zhdanava, Eric Q Wu, Simu K Thomas, Lei Chen
{"title":"Five-year direct costs of acute lymphoblastic leukemia pediatric patients undergoing allogeneic stem cell transplant.","authors":"Richard T Maziarz,&nbsp;Annie Guérin,&nbsp;Geneviève Gauthier,&nbsp;Julie Heroux,&nbsp;Maryia Zhdanava,&nbsp;Eric Q Wu,&nbsp;Simu K Thomas,&nbsp;Lei Chen","doi":"10.2217/ijh-2016-0001","DOIUrl":"https://doi.org/10.2217/ijh-2016-0001","url":null,"abstract":"<p><strong>Aim: </strong>To assess the 5-year healthcare resource utilization (HRU) and direct payer costs following allogeneic hematopoietic stem cell transplants (HSCTs) in acute lymphoblastic leukemia pediatric patients using data from two large US administrative databases.</p><p><strong>Patients & methods: </strong>Among the 209 patients with acute lymphoblastic leukemia, HRU and costs were described over the up to 5 years after the HSCT.</p><p><strong>Results: </strong>HRU and costs following the HSCTs were substantial. The highest average costs and most intensive HRU were observed within the first year following the HSCTs (49 outpatient visits; 29 laboratory service visits; 68 inpatient days), with a first year cost of US$683,099 and substantial costs over the following years.</p><p><strong>Conclusion: </strong>HRU and direct costs associated with allogeneic HSCTs are substantial.</p>","PeriodicalId":14166,"journal":{"name":"International Journal of Hematologic Oncology","volume":"5 2","pages":"63-75"},"PeriodicalIF":0.0,"publicationDate":"2016-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/ijh-2016-0001","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36568855","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 7
Cancer treatment in the extreme elderly: case study of a 100-year-old lymphoma patient. 极端老年人的癌症治疗:一位100岁淋巴瘤患者的病例研究。
International Journal of Hematologic Oncology Pub Date : 2016-09-01 Epub Date: 2016-08-19 DOI: 10.2217/ijh-2016-0005
Peter J Gilbar, Howard Mutsando, Joshua P Richmond, Ronald B Middleton
{"title":"Cancer treatment in the extreme elderly: case study of a 100-year-old lymphoma patient.","authors":"Peter J Gilbar,&nbsp;Howard Mutsando,&nbsp;Joshua P Richmond,&nbsp;Ronald B Middleton","doi":"10.2217/ijh-2016-0005","DOIUrl":"https://doi.org/10.2217/ijh-2016-0005","url":null,"abstract":"<p><p>Limited data are available on the treatment of older adults with cancer. Comorbidities may preclude the administration of effective therapies, particularly in the extreme elderly. Comprehensive geriatric assessment can identify specific weaknesses of the patient and predict unexpected toxicities, thus enabling an optimized treatment strategy in this population. We report a case of the successful management of a 99-year-old female lymphoma patient with a strong wish for active treatment to improve quality of life and prolong survival past her 100th birthday. This case demonstrates that cancer treatment in the extreme elderly is possible and highlights the need for a formalized treatment plan based on geriatric assessment, frank discussion with patients and families, and defined goals of therapy.</p>","PeriodicalId":14166,"journal":{"name":"International Journal of Hematologic Oncology","volume":"5 2","pages":"59-62"},"PeriodicalIF":0.0,"publicationDate":"2016-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/ijh-2016-0005","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36612059","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Diagnostic and treatment of adult Philadelphia chromosome-positive acute lymphoblastic leukemia. 成人费城染色体阳性急性淋巴细胞白血病的诊断和治疗。
International Journal of Hematologic Oncology Pub Date : 2016-09-01 Epub Date: 2016-09-23 DOI: 10.2217/ijh-2016-0009
Xavier Thomas, Maël Heiblig
{"title":"Diagnostic and treatment of adult Philadelphia chromosome-positive acute lymphoblastic leukemia.","authors":"Xavier Thomas, Maël Heiblig","doi":"10.2217/ijh-2016-0009","DOIUrl":"10.2217/ijh-2016-0009","url":null,"abstract":"<p><p>The outcome of adult patients with Philadelphia chromosome-positive (Ph<sup>+</sup>) acute lymphoblastic leukemia (ALL) has improved substantially with the introduction of tyrosine kinase inhibitors (TKIs). TKIs are now integral components of therapy for Ph<sup>+</sup> ALL. The current consensus is that they improve patient outcomes compared with historical control patients treated with chemotherapy alone, and increase the number of patients able to receive stem cell transplant. New challenges have emerged with respect to induction of resistance mainly via Abelson tyrosine kinase mutations. Several novel kinase inhibitors with significantly more potent antileukemic activity are currently being developed. Furthermore novel immune therapies, which recruit or modify patient's own T cells to fight leukemic cells, are being developed and could find an important place in Ph<sup>+</sup> ALL therapy by few years. In this article, we reviewed treatment approaches in adults with Ph<sup>+</sup> ALL with a focus on TKIs and combined chemotherapy regimens.</p>","PeriodicalId":14166,"journal":{"name":"International Journal of Hematologic Oncology","volume":"5 2","pages":"77-90"},"PeriodicalIF":0.0,"publicationDate":"2016-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6171979/pdf/ijh-05-77.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36568857","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Erythrocyte encapsulated l-asparaginase (GRASPA) in acute leukemia. 急性白血病患者红细胞包埋的l-天冬酰胺酶（GRASPA）。
International Journal of Hematologic Oncology Pub Date : 2016-05-01 Epub Date: 2016-05-05 DOI: 10.2217/ijh-2016-0002
Xavier Thomas, Caroline Le Jeune
{"title":"Erythrocyte encapsulated l-asparaginase (GRASPA) in acute leukemia.","authors":"Xavier Thomas,&nbsp;Caroline Le Jeune","doi":"10.2217/ijh-2016-0002","DOIUrl":"10.2217/ijh-2016-0002","url":null,"abstract":"<p><p>l-asparaginase, an enzyme originally derived from <i>Escherichia coli</i>, represents a major drug in the treatment of acute lymphoblastic leukemia. However, the occurrence of major adverse effects often leads to early withdrawal of the enzyme. Main side effects include immune-allergic reactions, coagulopathy, pancreatitis and hepatic disorders. Novel asparaginase formulations and alternative sources have been developed to address this issue, but the results were not totally satisfactory. l-asparaginase loaded red blood cells (RBCs; GRASPA) represent a new asparaginase presentation with reduced immunological adverse reactions. RBCs protect l-asparaginase, enhance its half-life and reduce the occurrence of adverse events. We reviewed the history, biology and clinical experiences with l-asparaginase, and the characteristics and first clinical experiences with GRASPA in the treatment of acute leukemia.</p>","PeriodicalId":14166,"journal":{"name":"International Journal of Hematologic Oncology","volume":"5 1","pages":"11-25"},"PeriodicalIF":0.0,"publicationDate":"2016-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/ijh-2016-0002","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36558508","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 18
Targeting B-cell receptor signaling in leukemia and lymphoma: how and why? 靶向b细胞受体信号在白血病和淋巴瘤中的作用:如何以及为什么?
International Journal of Hematologic Oncology Pub Date : 2016-05-01 Epub Date: 2016-05-26 DOI: 10.2217/ijh-2016-0003
John C Allen, Fatima Talab, Joseph R Slupsky
{"title":"Targeting B-cell receptor signaling in leukemia and lymphoma: how and why?","authors":"John C Allen,&nbsp;Fatima Talab,&nbsp;Joseph R Slupsky","doi":"10.2217/ijh-2016-0003","DOIUrl":"https://doi.org/10.2217/ijh-2016-0003","url":null,"abstract":"<p><p>B-lymphocytes are dependent on B-cell receptor (BCR) signaling for the constant maintenance of their physiological function, and in many B-cell malignancies this signaling pathway is prone to aberrant activation. This understanding has led to an ever-increasing interest in the signaling networks activated following ligation of the BCR in both normal and malignant cells, and has been critical in establishing an array of small molecule inhibitors targeting BCR-induced signaling. By dissecting how different malignancies signal through BCR, researchers are contributing to the design of more customized therapeutics which have greater efficacy and lower toxicity than previous therapies. This allows clinicians access to an array of approaches to best treat patients whose malignancies have BCR signaling as a driver of pathogenesis.</p>","PeriodicalId":14166,"journal":{"name":"International Journal of Hematologic Oncology","volume":"5 1","pages":"37-53"},"PeriodicalIF":0.0,"publicationDate":"2016-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/ijh-2016-0003","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36612060","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 6
Propylene glycol-free melphalan as conditioning regimen for autologous transplantation in myeloma. 无丙二醇melphalan作为骨髓瘤自体移植的调理方案。
International Journal of Hematologic Oncology Pub Date : 2016-05-01 Epub Date: 2016-05-31 DOI: 10.2217/ijh-2015-0006
Omar S Aljitawi, Parameswaran Hari
{"title":"Propylene glycol-free melphalan as conditioning regimen for autologous transplantation in myeloma.","authors":"Omar S Aljitawi,&nbsp;Parameswaran Hari","doi":"10.2217/ijh-2015-0006","DOIUrl":"https://doi.org/10.2217/ijh-2015-0006","url":null,"abstract":"<p><p>High-dose melphalan has been the drug of choice for preparative regimens for autologous stem cell transplantation in multiple myeloma. Propylene-free melphalan (Evomela™) is a newer formulation of melphalan, which incorporates Captisol<sup>®</sup> to produce a stable product upon reconstitution. In addition to avoiding propylene glycol with its' potential side effects, this approach improves the overall stability of reconstituted melphalan and can ensure intended dose delivery. In this paper, we review the published literature regarding this formulation. We focus on its' chemistry, pharmacokinetics and clinically available data for its use in myeloma autologous stem cell transplantation setting.</p>","PeriodicalId":14166,"journal":{"name":"International Journal of Hematologic Oncology","volume":"5 1","pages":"5-10"},"PeriodicalIF":0.0,"publicationDate":"2016-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/ijh-2015-0006","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36558507","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Dielectrophoretic recovery of DNA from plasma for the identification of chronic lymphocytic leukemia point mutations. 血浆DNA介电恢复鉴定慢性淋巴细胞白血病点突变。
International Journal of Hematologic Oncology Pub Date : 2016-05-01 Epub Date: 2016-05-05 DOI: 10.2217/ijh-2015-0009
Sareh Manouchehri, Stuart Ibsen, Jennifer Wright, Laura Rassenti, Emanuela M Ghia, George F Widhopf, Thomas J Kipps, Michael J Heller
{"title":"Dielectrophoretic recovery of DNA from plasma for the identification of chronic lymphocytic leukemia point mutations.","authors":"Sareh Manouchehri,&nbsp;Stuart Ibsen,&nbsp;Jennifer Wright,&nbsp;Laura Rassenti,&nbsp;Emanuela M Ghia,&nbsp;George F Widhopf,&nbsp;Thomas J Kipps,&nbsp;Michael J Heller","doi":"10.2217/ijh-2015-0009","DOIUrl":"https://doi.org/10.2217/ijh-2015-0009","url":null,"abstract":"<p><strong>Aim: </strong>Circulating cell free (ccf) DNA contains information about mutations affecting chronic lymphocytic leukemia (CLL). The complexity of isolating DNA from plasma inhibits the development of point-of-care diagnostics. Here, we introduce an electrokinetic method that enables rapid recovery of DNA from plasma.</p><p><strong>Materials & methods: </strong>ccf-DNA was isolated from 25 µl of CLL plasma using dielectrophoresis. The DNA was used for PCR amplification, sequencing and analysis.</p><p><strong>Results: </strong>The ccf-DNA collected from plasma of 5 CLL patients revealed identical mutations to those previously identified by extracting DNA from CLL cells from the same patients.</p><p><strong>Conclusion: </strong>Rapid dielectrophoresis isolation of ccf-DNA directly from plasma provides sufficient amounts of DNA to use for identification of point mutations in genes associated with CLL progression.</p>","PeriodicalId":14166,"journal":{"name":"International Journal of Hematologic Oncology","volume":"5 1","pages":"27-35"},"PeriodicalIF":0.0,"publicationDate":"2016-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/ijh-2015-0009","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36612057","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 20
Myelodysplastic syndromes: from conductiong clinical trials of novel therapies to evaluating real-life effectiveness of exisiting therapies 骨髓增生异常综合征:从开展新疗法的临床试验到评估现有疗法的现实有效性
International Journal of Hematologic Oncology Pub Date : 2015-12-11 DOI: 10.2217/IJH.15.25
A. Zeidan
{"title":"Myelodysplastic syndromes: from conductiong clinical trials of novel therapies to evaluating real-life effectiveness of exisiting therapies","authors":"A. Zeidan","doi":"10.2217/IJH.15.25","DOIUrl":"https://doi.org/10.2217/IJH.15.25","url":null,"abstract":"Amer Zeidan speaks to Laura Dormer, Editorial Director: Amer Zeidan is Assistant Professor of Medicine (Hematology) at Yale Cancer Center. He completed a hematology/oncology fellowship and a clinical research fellowship in myelodysplastic syndromes (MDS) at Johns Hopkins University where he also earned a Master of Health Science degree in Clinical Investigation. He received his MBBS degree from the Faculty of Medicine, University of Jordan (Amman, Jordan), before completing his internal medicine residency at Rochester General Hospital (USA). His clinical interest is in the management of hematologic malignancies. The focus of his clinical/translational research is the development of novel therapies for MDS and myeloid hematologic malignancies. The second area of research interest for him is effectiveness and outcomes research in hematologic malignancies, especially MDS.","PeriodicalId":14166,"journal":{"name":"International Journal of Hematologic Oncology","volume":"4 1","pages":"215-217"},"PeriodicalIF":0.0,"publicationDate":"2015-12-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/IJH.15.25","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"68221529","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信